---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056977"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:18:09.483113+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024

## Summary
- Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.
- Cash, equivalents, and investments total $901.0M as of March 31, 2024, partly from $350M private placement in Feb.
- Paltusotine PATHFNDR-2 Phase 3 met primary and all secondary endpoints; NDA submission expected in 2H 2024.
- Initial atumelnant Phase 2 results in CAH and Cushing's to be presented at ENDO 2024 (June 1-4).
- Plan to initiate paltusotine Phase 3 in carcinoid syndrome by end of 2024 pending FDA discussions.

## SEC filing metadata
- accession: 0000950170-24-056977
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/0000950170-24-056977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/crnx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056977
- JSON: https://secwatch.observer/filing/0000950170-24-056977.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056977.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million, net income $66.9 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $0.6 million
  - Net income: $66.9 million
  - Result: reported results
  source text: of $5.6 million. • Net loss for the three months ended March 31, 2024, was $66.9 million, compared to a net loss of $46.0 million for the same period in 2023. • Revenues were$0.6 million for the three months ended March 31, 2024, compared to $2.7 million for the same period in 2023. Revenues were derived from licensing arrangements for our paltusotine product
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/0000950170-24-056977-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.